Diagnostics

Elephas Biosciences adds legendary oncologist Dr. Skip Burris to its board, a pivotal move to commercialize a platform that predicts immunotherapy success.

Viz.ai expands its AI care platform into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative neuroimaging to nearly 2,000 hospitals.

AI can now find hidden heart risks in old CT scans, a market set to boom. But as doctors warn, the code is the easy part; the human factor is not.

Ashok Soota's Happiest Health is betting on a tech-infused, 'away-from-hospital' model. Can its new Bengaluru clinics redefine urban healthcare?

Covera Health's new Chief Clinical Officer isn't just another exec. Dr. Evan Raff's unique background signals a shift from AI hype to real-world results.

CorePlus's landmark integration of an AI-powered test marks a pivotal moment for personalized medicine and health equity in the Caribbean.

New AI tools are moving beyond if a cognitive task is done to how. This shift promises earlier detection, personalized care, and a new era for brain health.

A new study validates a blood test with near-perfect accuracy in MS relapse detection, signaling a strategic shift from imaging to biological data in neurology.

A South Korean diagnostics firm is launching a massive study to create universal testing standards. Can real-world data finally close the global healthcare gap?

A new partnership aims to turn saliva into a data-rich asset, signaling a major shift in the health tech market from reactive treatment to proactive care.

A Cambridge medtech firm has formed a global advisory board to fast-track its revolutionary 10-minute stroke test, a strategic move to disrupt pre-hospital care.

A new company aims to fix a multi-billion dollar problem in drug development by using advanced biomarker tests to find the right patients before they even start.

For millions with the debilitating condition dysautonomia, diagnosis is a long, frustrating journey. A new technology promises to replace subjective guesswork with hard data.

A new $200K award isn't just a grant; it's a strategic bet on systems engineering to fix a diagnostic pathway where 70% of lung cancer cases are found too late.

YD Bio is expanding its U.S. lab network, but the real story is its strategy: turning diagnostic tests into a vast data engine to power the future of cancer research.

Neurophet's AI software, now at Raffles Medical, analyzes brain MRIs in minutes, offering a powerful new weapon in the fight against dementia and MS in Asia.

After completing massive studies, the Utah firm is readying an FDA submission that could move gold-standard diagnostics from the lab to your local clinic.

An Oxford startup's AI-powered blood test can detect cancer and heart disease in dogs from a single sample, heralding a shift from reactive to proactive care.

A new company is launching an AI-powered specialty to detect cancer before it forms. But can this personalized, oncologist-led model overcome hurdles of cost and access?